Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population

DNA and Cell Biology

Volumn 26, Issue 8, 2007, Pages 527-531

  Boke, Omer ^a   Gunes, Sezgin ^a   Kara, Nurten ^a   Aker, Servet ^a   Sahin, Ahmet Rifat ^a   Basar, Yildiz ^b   Bagci, Hasan ^a  

^a ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^b Psikotem Private Psychiatry Center   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; NEUROLEPTIC AGENT; RESTRICTION ENDONUCLEASE; SEROTONIN 2A RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; DRUG EXPOSURE; FEMALE; GENE AMPLIFICATION; GENE FREQUENCY; GENOTYPE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; SMOKING; TARDIVE DYSKINESIA; TURKEY (REPUBLIC);

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; COMORBIDITY; CYTOCHROME P-450 CYP1A2; DYSKINESIA, DRUG-INDUCED; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT2A; SCHIZOPHRENIA; SMOKING; TURKEY;

EID: 34547916392     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/dna.2007.0605     Document Type: Article

References (30)

1. Arranz, M.J., Munro, J., Owen, M.J., et al. (1998). Evidence for association between polymorphisms in the promoter and coding regions of the HTR2A receptor gene and response to clozapine. Mol. Psychiatry 3, 61-66.
2. Ball, S.E., Scatina, J., and Kao, J. (1999). Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of 3CYPA4. Clin. Pharmacol. Ther. 66, 288-294.
3. Basile, V.S., Özdemir, V., Masellis, M., et al. (2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizoprenia. Mol. Psychiatry 5, 410-417.
4. Basile, V.S., Özdemir, V., Masellis, M., et al. (2001). Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol. Psychiatry 6, 230-234.
5. Bhatia, T., Sabeeha, M.R., Shriharsh, V., et al. (2004). Clinical and familial correlates of tardive dyskinesia in India and Israel. Postgrad. Med. 50, 167-172.
6. Brosen, K. (1996). Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry. Ther. Drug Monit. 18, 393-396.
7. Chong, S.A., Tan, E.C., Tan, C.H., et al. (2003). Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J. Psychiatry Neurosci. 28, 185-189.
8. Deshpande, S.N., Varma, P.G., Semwal, P., et al. (2005). II. Serotonin receptor gene polymorphisms and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatr. Genet. 15, 157-158.
9. Fu, Y., Fan, C., Deng, H., et al. (2006). Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol. Sin. 27, 327-332.
10. Herken, H., Erdal, M.E., Boke, O., et al. (2003). Tardive dyskinesia is not associated with the polymorphism of HTR2A receptor gene, serotonin transporter gene and catechol-o-methyltransferance gene. Eur. Psychiatry 18, 77-81.
11. Kalow, W., and Tang, B.K. (1991). Caffeine as a metabolic probe; exploration of the enzyme-inducing effect of cigarette smoking. Clin. Pharmacol. Ther. 49, 44-48.
12. Lerer, B., Segman, R.H., Tan, E.C., et al. (2005). Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int. J. Neuropsychopharmacol. 28, 411-425.
13. Marcello, F.P., Vanessa, C., Abilio, R.H., et al. (2003). Effects of valproic acid on an animal model of tardive dyskinesia. Behav. Brain Res. 142, 229-233.
14. Matsumoto, C., Ohmori, O., Shinkai, T., et al. (2003). Genetic association analysis of functional polymorphisms in the cytochrome P4501A2(CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr. Genet. 14, 209-213.
15. Meyer, U.A. (1994). Pharmacogenetics: the slow, the rapid and the ultrarapid. Proc. Natl. Acad. Sci. USA 91, 1983-1984.
16. Miller, S.A., Dykes, D.D., and Polsky, H.F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215.
17. Muller, D.J., Schulze, T.G., Knapp, M., et al. (2001). Familial occurrence of tardive dyskinesia. Acta Psychiatr. Scand. 104, 374-379.
18. Ohmori, O., Shinkai, T., Hori, H., et al. (2002). Genetic association analysis of 5HT-6 receptor gene polymorphism (267 C/T) with tardive dyskinesia. Psychiatry Res. 110, 97-102.
19. Okey, A.B. (1990). Enzyme induction in the cytochrome P450 system. Pharmacol. Ther. 45, 241-298.
20. Parsons, M.J., D'souza, U.M., Arranz, M.J., et al. (2004). The -1438A/G polymorphism in the 5-hydroxytryptamine type 2A receptor gene affects promoter activity. Biol. Psychiatry 56, 406-410.
21. Rosengarten, H., Schweitzer, J.W., and Friedhoff, A.J. (1993). A mechanism underlying neuroleptic-induced oral dyskinesis in rats. Pol. J. Pharmacol. 45, 391-398.
22. Sachdev, P.S. (2000). The current status of tardive dyskinesia. Aust. N. Z. J. Psychiatry 34, 355-369.
23. Schooler, N.R., and Kane, J.M. (1982). Research diagnosis for tardive dyskinesia. Arch. Gen. Psychiatry 39, 486-487.
24. Schulze, T.G., Schumache, J., Muller, D.J., et al. (2001). Lack of association between a functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 105, 498-501.
25. Segman, R.H., Heresco-Levy, U., Finkel, B., et al. (2001). Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry 6, 225-229.
26. Tan, E.C., Chong, S.A., Mahendran, R., et al. (2001). Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol. Psychiatry 50, 144-147.
27. Tiwari, A.K., Deshpande, S.N., Rao, A.R., et al. (2005a). Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphism. Schizophr. Res. 75, 21-26.
28. Tiwari, A.K., Deshpande, S.N., Rao, A.R., et al. (2005b). Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J. 5, 60-69.
29. Yager, J., and Gitlin, M.J. (2005). Clinical manifestations of psychiatric disorders. In Comprehensive Textbook of Psychiatry. B.J. Sadock and V.A. Sadock, eds. (Lippincott Williams and Wilkins, Philadelphia, PA), pp. 964-1002.
30. Yassa, R., and Annath, J. (1981). Familial tardive dyskinesia. Am. J. Psychiatry 138, 1618-1619.